The city of Spokane, Washington, currently has 8 active clinical trials seeking participants for Parkinson's Disease research studies.
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
Recruiting
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
03/17/2025
Locations: Inland Northwest Research, Spokane, Washington
Conditions: Parkinson Disease
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Recruiting
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to evaluate how effective ABBV-951 is in treating adult participants with advanced PD in real world setting. ABBV-951 (foslevodopa/foscarbidopa) is an approved drug for the treatment of Parkinson's Disease. The main ROSSINI study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Inland Northwest Research /ID# 253460, Spokane, Washington
Conditions: Parkinson's Disease (PD)
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Inland Northwest Research, Spokane, Washington
Conditions: Parkinson's Disease
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424, 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/25/2025
Locations: Inland Northwest Research, Spokane, Washington
Conditions: Parkinson Disease
Lu AF28996 in Participants With Parkinson's Disease (PD)
Recruiting
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
Gender:
ALL
Ages:
Between 35 years and 85 years
Trial Updated:
02/12/2025
Locations: Inland Nortwest Research, Spokane, Washington
Conditions: Parkinson Disease
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
Recruiting
In this study, researchers will learn more about BIIB122 in participants with early-stage Parkinson's disease (PD). The study will include adults aged 30 to 80 who were diagnosed with PD within 2 years of starting the study. The main objective of the study is to learn about the effect BIIB122 has on slowing down the worsening of PD symptoms. The main question researchers want to answer is: - How long does it take for PD symptoms to worsen during BIIB122 treatment? Researchers will answer this... Read More
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
02/04/2025
Locations: Inland Northwest Research, Spokane, Washington
Conditions: Parkinson Disease
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/21/2024
Locations: Clinical Site, Spokane, Washington
Conditions: Parkinson Disease
Parkinson's Foundation PD GENEration Genetic Registry
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Inland Northwest Research, Spokane, Washington
Conditions: Parkinson's Disease